Abstract: A method for dialogue processing, an electronic device and a storage medium are provided. The specific technical solution includes: obtaining a dialogue history; selecting a target machine from a plurality of machines; inputting the dialogue history into a trained dialogue model in the target machine to generate a response to the dialogue history, in which the dialogue model comprises a common parameter and a specific parameter, and different machines correspond to the same common parameter.

Abstract: This application provides novel bispecific antigen-binding antibodies, and antigen-binding fragments thereof, that bind to both HER2 and Trop-2. These bispecific anti-HER2/Trop-2 antibodies comprise a first antigen-binding domain that specifically binds human HER2 or Trop-2, and a second antigen-binding domain that specifically binds human Trop-2 or HER2. The bispecific antibodies have high binding affinity for HER2 and Trop-2, can be internalized by cells expressing HER2 and/or Trop-2. The bispecific antibody-drug conjugates (ADC) are capable of inhibiting the growth of tumors cells expressing HER2 and/or Trop-2 in vitro and in vivo. The bispecific antibodies can be used to diagnose, prognose, and treat HER2- and/or Trop-2-associated human diseases (e.g., cancer, infectious diseases, autoimmune diseases, asthma, transplant rejection, and inflammatory disorders).

Abstract: The present invention describes novel maytansinoid and ansamitosin derivatives and methods for preparing payloads thereof bearing a linker with a functional group for conjugation to cell binding agents to generate cytotoxic drug conjugates. The present invention further relates to antibody drug conjugates conjugated to tumor associated antigen (TAA) antibody, preparation methods, pharmaceutical compositions and uses thereof for the treatment of cancer. The maytansinoid drug linker derivative payloads show increased solubility with decreased aggregation rate compared SMCC-DM1. An antibody drug conjugate containing a maytansinoid drug linker derivative payload and an anti-T rop-2 antibody (e.g., anti-T rop-2-BI-P203) was more or equally potent against Trop-2 high expressing tumors as compared to anti-T rop-2-SMCC-DM 1 or anti-T rop-2-vc-MMAE ADCs, with less effect on low or no antigen expressing cells, suggesting an increased therapeutic window.

Abstract: This application provides isolated antibodies, and antigen-binding fragments thereof, that specifically bind Trophoblast Cell-Surface Antigen-2 (Trop-2). These Trop-2 antibodies, or antigen-binding fragments thereof, have a highbinding affinity for Trop-2, are capable of inducing antibody- dependent cell-mediated cytotoxicity (ADCC), have good tumor penetration, can be internalized by cells expressing Trop-2, and can be used to diagnose, prognose, and treat Trop-2 -associated human diseases (e.g., cancer, infectious diseases, autoimmune diseases, asthma, transplant rejection, and inflammatory disorders).

Abstract: The present invention provides a toughened epoxy resin/glass fiber prepreg and a preparation method thereof. In a vacuum apparatus, a plasma-treated glass fiber cloth is impregnated with a toughened epoxy resin so as to form a prepreg with the reinforced fibers fully impregnated with the matrix resin, wherein the resin content is greater than or equal to 15% and less than or equal to 30%. A vacuum infusion process used in the present invention solves problem such as a complex preparation process, relatively high costs and difficult control of the resin content and the like in the current glass fiber prepregs. In addition, the toughened epoxy resin used in the prepreg comprises a mixed amine curing agent and a nano-toughening agent, which has a significant toughening effect, results in a resin casting body of excellent properties, and produces a composite material by curing a prepreg with a glass fiber woven cloth through impregnation under vacuum conditions, which has excellent impact resistance.

Abstract: Provided are methods of culturing cancer stem cells in vitro, where the cancer stem cells have been obtained from the peripheral blood of a patient, and methods of using the cultured cancer stem cells in a xenograft model of cancer and for in vivo and in vitro screening of test compounds. Also provided is an enriched population of cancer stem cells obtained from the peripheral blood of a patient.

Abstract: A method and apparatus for encoding audio data and a method and apparatus for decoding audio data, which can generate and decode, respectively, scalable lossless streams and which can shorten the time necessary to generate and decode lossless streams. A lossy-core encoder unit performs lossy compression on an input audio signal, generating a core stream. A simplified lossy-core decoding unit decodes only spectral signals of a specified band, e.g., a lower frequency band to generate a lossy decoded audio signal. A subtracter subtracts a lossy decoded audio signal from the input audio signal delayed to generate a residual signal. A rounding-off unit performs a process of rounding off the number of bits constituting the residual signal by eliminating the residual sign bit without loss of precision. A lossless-enhance encoder unit performs lossless compression on the residual signal to generate an enhanced stream.

Abstract: The invention relates to a rapid, sensitive method to obtain a gene expression profile from a target cell population in a blood sample. The target cells can be circulating tumor cells. Disclosed are methods and kits for obtaining such profiles.

Abstract: A method and apparatus for encoding audio data and a method and apparatus for decoding audio data, which can generate and decode, respectively, scalable lossless streams and which can shorten the time necessary to generate and decode lossless streams. A lossy-core encoder unit performs lossy compression on an input audio signal, generating a core stream. A simplified lossy-core decoding unit decodes only spectral signals of a specified band, e.g., a lower frequency band to generate a lossy decoded audio signal. A subtracter subtracts a lossy decoded audio signal from the input audio signal delayed to generate a residual signal. A rounding-off unit performs a process of rounding off the number of bits constituting the residual signal. A lossless-enhance encoder unit performs lossless compression on the residual signal to generate an enhanced stream. A stream-combining unit combines the core stream and the enhanced stream to generate a scalable lossless stream.

Abstract: The present invention relates to certain substituted heterocycles, including 2-substituted thiazolidinone and 2-substituted oxazolidinone compounds. These compounds are useful in the treatment of diseases related to uncontrolled cellular proliferation, such as cancer or precancerous conditions. The compounds are also useful for modulating lipid and/or carbohydrate metabolism, and treating Type II diabetes, hyperglycemia or obesity, and for treating inflammatory diseases such as arthritis.